Addition of an extra dose of salmeterol Diskus® to conventional dose of salmeterol Diskus® in patients with COPD

M. Cazzola, P. Santus, F. Castagna, F. Di Marco, C. Terzano, M. G. Matera, S. Centanni

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

Patients experiencing dyspnoea can request an additional dose of salmeterol during the dose interval for the control of their symptoms, although under treatment with salmeterol. In this study we have explored the effects on respiratory function of an additive dose of salmeterol Diskus® in 15 chronic obstructive pulmonary disease (COPD) patients in regular treatment with a conventional dose of 50 μg salmeterol. On two different days, patients inhaled 50 μg Diskus®. After 240 min, they inhaled additional 50 μg salmeterol Diskus® (salmeterol arm) or placebo Diskus® (placebo arm). Lung function was controlled before first drug administration and 0.5, 1, 2, 3, 4, 4.5, 6, 8, 10, and 12 h thereafter. The mean (95% CI) peak increase in FEV1 from baseline was reached after 4 h in the salmeterol arm (0.174 L; 0.144-0204) and after 5 h (0.141 L; 0.115-0.168) in the placebo arm; after 12 h, the mean (95% CI) increase in FEV1 from basal values was still 0.149 L (0.119-0.179) in salmeterol arm, but only 0.041 L (0.017-0.064) in placebo arm. The mean (95% CI) FEV1 AUC0-12h for all patients were 2.01 (1.72-2.30) L when salmeterol was added and 1.30 (1.03-1.58) L when placebo was inhaled. The difference (mean; 95% CI) between the FEV1 AUC0-12h of the two arms (0.71 L; 0.47-0.95) was statistically significant (P <0.0001), although the difference (mean; 95% CI) between the FEV1 AUC0-4h of the two treatments (0.08 L; -0.02-0.18) was not statistically significant (P=0.126). The addition of an extra dose of salmeterol did not significantly increase the heart rate or decrease the SpO2. This study suggests that the addition of an extra dose of salmeterol does not give room for further increase in peak FEV1, but the effect of adding salmeterol to salmeterol is largely additive when considering the duration of action and safe.

Original languageEnglish
Pages (from-to)439-443
Number of pages5
JournalRespiratory Medicine
Volume96
Issue number6
DOIs
Publication statusPublished - Jun 1 2002

Fingerprint

Chronic Obstructive Pulmonary Disease
Placebos
Salmeterol Xinafoate
Dyspnea
Therapeutics
Heart Rate
Lung

Keywords

  • COPD
  • Extra dose
  • Salmeterol

ASJC Scopus subject areas

  • Pulmonary and Respiratory Medicine

Cite this

Cazzola, M., Santus, P., Castagna, F., Di Marco, F., Terzano, C., Matera, M. G., & Centanni, S. (2002). Addition of an extra dose of salmeterol Diskus® to conventional dose of salmeterol Diskus® in patients with COPD. Respiratory Medicine, 96(6), 439-443. https://doi.org/10.1053/rmed.2001.1279

Addition of an extra dose of salmeterol Diskus® to conventional dose of salmeterol Diskus® in patients with COPD. / Cazzola, M.; Santus, P.; Castagna, F.; Di Marco, F.; Terzano, C.; Matera, M. G.; Centanni, S.

In: Respiratory Medicine, Vol. 96, No. 6, 01.06.2002, p. 439-443.

Research output: Contribution to journalArticle

Cazzola, M, Santus, P, Castagna, F, Di Marco, F, Terzano, C, Matera, MG & Centanni, S 2002, 'Addition of an extra dose of salmeterol Diskus® to conventional dose of salmeterol Diskus® in patients with COPD', Respiratory Medicine, vol. 96, no. 6, pp. 439-443. https://doi.org/10.1053/rmed.2001.1279
Cazzola, M. ; Santus, P. ; Castagna, F. ; Di Marco, F. ; Terzano, C. ; Matera, M. G. ; Centanni, S. / Addition of an extra dose of salmeterol Diskus® to conventional dose of salmeterol Diskus® in patients with COPD. In: Respiratory Medicine. 2002 ; Vol. 96, No. 6. pp. 439-443.
@article{f466b3aab91040ed88bc50149e875932,
title = "Addition of an extra dose of salmeterol Diskus{\circledR} to conventional dose of salmeterol Diskus{\circledR} in patients with COPD",
abstract = "Patients experiencing dyspnoea can request an additional dose of salmeterol during the dose interval for the control of their symptoms, although under treatment with salmeterol. In this study we have explored the effects on respiratory function of an additive dose of salmeterol Diskus{\circledR} in 15 chronic obstructive pulmonary disease (COPD) patients in regular treatment with a conventional dose of 50 μg salmeterol. On two different days, patients inhaled 50 μg Diskus{\circledR}. After 240 min, they inhaled additional 50 μg salmeterol Diskus{\circledR} (salmeterol arm) or placebo Diskus{\circledR} (placebo arm). Lung function was controlled before first drug administration and 0.5, 1, 2, 3, 4, 4.5, 6, 8, 10, and 12 h thereafter. The mean (95{\%} CI) peak increase in FEV1 from baseline was reached after 4 h in the salmeterol arm (0.174 L; 0.144-0204) and after 5 h (0.141 L; 0.115-0.168) in the placebo arm; after 12 h, the mean (95{\%} CI) increase in FEV1 from basal values was still 0.149 L (0.119-0.179) in salmeterol arm, but only 0.041 L (0.017-0.064) in placebo arm. The mean (95{\%} CI) FEV1 AUC0-12h for all patients were 2.01 (1.72-2.30) L when salmeterol was added and 1.30 (1.03-1.58) L when placebo was inhaled. The difference (mean; 95{\%} CI) between the FEV1 AUC0-12h of the two arms (0.71 L; 0.47-0.95) was statistically significant (P <0.0001), although the difference (mean; 95{\%} CI) between the FEV1 AUC0-4h of the two treatments (0.08 L; -0.02-0.18) was not statistically significant (P=0.126). The addition of an extra dose of salmeterol did not significantly increase the heart rate or decrease the SpO2. This study suggests that the addition of an extra dose of salmeterol does not give room for further increase in peak FEV1, but the effect of adding salmeterol to salmeterol is largely additive when considering the duration of action and safe.",
keywords = "COPD, Extra dose, Salmeterol",
author = "M. Cazzola and P. Santus and F. Castagna and {Di Marco}, F. and C. Terzano and Matera, {M. G.} and S. Centanni",
year = "2002",
month = "6",
day = "1",
doi = "10.1053/rmed.2001.1279",
language = "English",
volume = "96",
pages = "439--443",
journal = "Respiratory Medicine",
issn = "0954-6111",
publisher = "W.B. Saunders Ltd",
number = "6",

}

TY - JOUR

T1 - Addition of an extra dose of salmeterol Diskus® to conventional dose of salmeterol Diskus® in patients with COPD

AU - Cazzola, M.

AU - Santus, P.

AU - Castagna, F.

AU - Di Marco, F.

AU - Terzano, C.

AU - Matera, M. G.

AU - Centanni, S.

PY - 2002/6/1

Y1 - 2002/6/1

N2 - Patients experiencing dyspnoea can request an additional dose of salmeterol during the dose interval for the control of their symptoms, although under treatment with salmeterol. In this study we have explored the effects on respiratory function of an additive dose of salmeterol Diskus® in 15 chronic obstructive pulmonary disease (COPD) patients in regular treatment with a conventional dose of 50 μg salmeterol. On two different days, patients inhaled 50 μg Diskus®. After 240 min, they inhaled additional 50 μg salmeterol Diskus® (salmeterol arm) or placebo Diskus® (placebo arm). Lung function was controlled before first drug administration and 0.5, 1, 2, 3, 4, 4.5, 6, 8, 10, and 12 h thereafter. The mean (95% CI) peak increase in FEV1 from baseline was reached after 4 h in the salmeterol arm (0.174 L; 0.144-0204) and after 5 h (0.141 L; 0.115-0.168) in the placebo arm; after 12 h, the mean (95% CI) increase in FEV1 from basal values was still 0.149 L (0.119-0.179) in salmeterol arm, but only 0.041 L (0.017-0.064) in placebo arm. The mean (95% CI) FEV1 AUC0-12h for all patients were 2.01 (1.72-2.30) L when salmeterol was added and 1.30 (1.03-1.58) L when placebo was inhaled. The difference (mean; 95% CI) between the FEV1 AUC0-12h of the two arms (0.71 L; 0.47-0.95) was statistically significant (P <0.0001), although the difference (mean; 95% CI) between the FEV1 AUC0-4h of the two treatments (0.08 L; -0.02-0.18) was not statistically significant (P=0.126). The addition of an extra dose of salmeterol did not significantly increase the heart rate or decrease the SpO2. This study suggests that the addition of an extra dose of salmeterol does not give room for further increase in peak FEV1, but the effect of adding salmeterol to salmeterol is largely additive when considering the duration of action and safe.

AB - Patients experiencing dyspnoea can request an additional dose of salmeterol during the dose interval for the control of their symptoms, although under treatment with salmeterol. In this study we have explored the effects on respiratory function of an additive dose of salmeterol Diskus® in 15 chronic obstructive pulmonary disease (COPD) patients in regular treatment with a conventional dose of 50 μg salmeterol. On two different days, patients inhaled 50 μg Diskus®. After 240 min, they inhaled additional 50 μg salmeterol Diskus® (salmeterol arm) or placebo Diskus® (placebo arm). Lung function was controlled before first drug administration and 0.5, 1, 2, 3, 4, 4.5, 6, 8, 10, and 12 h thereafter. The mean (95% CI) peak increase in FEV1 from baseline was reached after 4 h in the salmeterol arm (0.174 L; 0.144-0204) and after 5 h (0.141 L; 0.115-0.168) in the placebo arm; after 12 h, the mean (95% CI) increase in FEV1 from basal values was still 0.149 L (0.119-0.179) in salmeterol arm, but only 0.041 L (0.017-0.064) in placebo arm. The mean (95% CI) FEV1 AUC0-12h for all patients were 2.01 (1.72-2.30) L when salmeterol was added and 1.30 (1.03-1.58) L when placebo was inhaled. The difference (mean; 95% CI) between the FEV1 AUC0-12h of the two arms (0.71 L; 0.47-0.95) was statistically significant (P <0.0001), although the difference (mean; 95% CI) between the FEV1 AUC0-4h of the two treatments (0.08 L; -0.02-0.18) was not statistically significant (P=0.126). The addition of an extra dose of salmeterol did not significantly increase the heart rate or decrease the SpO2. This study suggests that the addition of an extra dose of salmeterol does not give room for further increase in peak FEV1, but the effect of adding salmeterol to salmeterol is largely additive when considering the duration of action and safe.

KW - COPD

KW - Extra dose

KW - Salmeterol

UR - http://www.scopus.com/inward/record.url?scp=0036591413&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0036591413&partnerID=8YFLogxK

U2 - 10.1053/rmed.2001.1279

DO - 10.1053/rmed.2001.1279

M3 - Article

C2 - 12117044

AN - SCOPUS:0036591413

VL - 96

SP - 439

EP - 443

JO - Respiratory Medicine

JF - Respiratory Medicine

SN - 0954-6111

IS - 6

ER -